P21 (P021)

InvestigationalNeurotrophic Peptide ResearchBrain, mood & sleepLongevity & cellular
5.0

Neutral, BioHarmony verdict

BioHarmony score 5.0 out of 10

P21 (P021) is a CNTF-derived peptidomimetic that crosses the blood-brain barrier and, in mice, raises BDNF, lifts hippocampal neurogenesis, and lowers tau pathology in Alzheimer's models. The catch is total. There are zero human trials, the single independent in-vivo replication failed to reproduce the BDNF benefit, and almost all the positive work comes from the inventor, who co-founded the company…

Read full report

What is P21 (P021)?

P21, also written P021, is a lab-designed peptide built from a small piece of ciliary neurotrophic factor, a natural growth factor for nerve cells. Researchers mapped the most active fragment of that protein, then bolted on a bulky adamantane group so the peptide could cross the blood-brain barrier and resist breakdown.

From the BioHarmony report, reviewed Sep 8, 2026.

Saved on this device only.

How it is thought to work

Raises BDNF and inhibits LIF signaling, which lowers GSK-3beta and reduces tau hyperphosphorylation

Safety watch-outs

  • Any new or worsening seizure, aura, or unusual neurological symptom: stop immediately, since growth-factor and neurogenesis modulation has…
  • Active or prior cancer: do not use, since chronically raising trophic and pro-proliferative signaling is a theoretical concern with no…
  • Injection-site redness, swelling, warmth, or fever: stop and seek care, since grey-market injectables carry sterility and infection risk.
  • Any unexpected reaction at all: there is no human safety baseline, so treat anything new as a reason to stop and reassess.

Full risk profile in the BioHarmony report.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

No approved-label or study protocol is recorded for P21 (P021) yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalInvestigational
CompoundingEligibility not established.

The registry's P21 entry refers to P021, a CNTF-derived neurotrophic peptide mimetic. The reviewed evidence is preclinical, including mouse models of Alzheimer-like pathology, and does not establish human safety or effectiveness.

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.